<DOC>
	<DOCNO>NCT02018172</DOCNO>
	<brief_summary>The study perform collect long-term data treatment adherence patient 's acceptability Zomacton®10 mg administer Zomajet® Vision X device patient growth hormone deficiency Turner 's syndrome .</brief_summary>
	<brief_title>Evaluation Adherence Patient Acceptability Zomacton® Treatment With Zomajet® Vision X Device</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Patient growth hormone deficiency , 1 . Diagnosis growth hormone deficiency proven appropriate exploration 2 . Size ≤ 2 Standard Deviation ( SD ) accord French reference 3 . Growth velocity previous year inferior normal age ( 1SD ) &lt; 4cm/year Growth deficiency due Turner 's syndrome 1 . Turner 's syndrome confirm karyotype 2 . Patient 's size ≤ 2 SD accord French reference 3 . Bone age &lt; 12 year Patient require minimum 18 month treatment . There exclusion criterion except contraindication Zomacton® 10 mg</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>